GMAB vs. SMMT: Genmab vs. Summit Therapeutics Stock Comparison
How do Genmab (GMAB) and Summit Therapeutics (SMMT) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Genmab (GMAB) and Summit Therapeutics (SMMT) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
Summit Therapeutics (SMMT) trades as ordinary local shares, while Genmab (GMAB) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | GMAB | SMMT |
|---|---|---|
| Name | Genmab A/S American Depositary Shares | Summit Therapeutics Inc. |
| Country/Region | Denmark | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 32.98 billion USD | 13.06 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | June 1, 2009 | March 5, 2015 |
| Security Type | ADR | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | GMAB | SMMT |
|---|---|---|
| Total Return (1Y) | 91.17% | -2.48% |
| Total Return (3Y, Annualized) | 20.70% | 116.18% |
| Total Return (5Y, Annualized) | 3.98% | 26.89% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
Summit Therapeutics (SMMT) reports a negative beta of -1.51, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Genmab (GMAB) has a non-negative beta of 0.72.
| Metric | GMAB | SMMT |
|---|---|---|
| Volatility (1Y, Annualized) | 45.68% | 75.06% |
| Beta (5Y) | 0.72 | -1.51 |
| Max Drawdown (5Y) | -61.79% | -87.64% |
| Avg. Volume (3M) | 4.09M | 6.19M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | GMAB | SMMT |
|---|---|---|
| Sharpe Ratio (1Y) | 1.90 | -0.09 |
| Sortino Ratio (1Y) | 3.82 | -0.13 |
Profitability
ROE (TTM)
Summit Therapeutics (SMMT) reports a negative ROE of -220.01%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Genmab (GMAB) reports 12.07%, ranking against industry peers normally.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
12.07%
- Max
- 109.18%
- GMAB
- 12.07%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
-220.01%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- SMMT
- -220.01%
Net Margin (TTM)
Genmab (GMAB) at 16.97% retains a top-quartile share of revenue as profit, ahead of Summit Therapeutics (SMMT) at 0.00%, which keeps about the industry-typical share.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.97%
- Max
- 18.05%
- GMAB
- 16.97%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 18.05%
- Q3
- 4.78%
- SMMT
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Genmab (GMAB) at 37.15% operates in the top operating margin quartile, ahead of Summit Therapeutics (SMMT) at 0.00%, which runs around its industry’s norm.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
37.15%
- Max
- 83.12%
- GMAB
- 37.15%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 83.12%
- Q3
- 14.77%
- SMMT
- 0.00%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | GMAB | SMMT |
|---|---|---|
| ROE (TTM) | 12.07% | -220.01% |
| ROA (TTM) | 8.24% | -111.99% |
| Net Margin (TTM) | 16.97% | 0.00% |
| Operating Margin (TTM) | 37.15% | 0.00% |
| Gross Margin (TTM) | 92.67% | 0.00% |
Growth
Revenue Growth
Only one side can be read here: Genmab (GMAB) reports revenue growth of 19.19%, ranked against its industry; Summit Therapeutics (SMMT) has no revenue growth figure this period.
EPS Growth
Only one side can be read here: Genmab (GMAB) reports EPS growth of -9.23%, ranked against its industry; Summit Therapeutics (SMMT) has no EPS growth figure this period.
Growth Metrics
| Metric | GMAB | SMMT |
|---|---|---|
| Revenue Growth (YoY) | 19.19% | -- |
| Revenue Growth (3Y CAGR) | 21.23% | -- |
| EPS Growth (YoY) | -9.23% | -- |
| EPS Growth (3Y CAGR) | 8.48% | -- |
Financial Strength
Current Ratio (MRQ)
Summit Therapeutics (SMMT) at 5.99 keeps current ratio within its industry’s typical mid-range, while Genmab (GMAB) at 2.45 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for GMAB.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.45
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- GMAB
- 2.45
- Min
- 0.10
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.99
- Max
- 25.13
- Q3
- 12.13
- SMMT
- 5.99
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Summit Therapeutics (SMMT) at 0.04 carries an industry-typical debt-to-equity mix, while Genmab (GMAB) at 0.82 uses more debt funding than most peers.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.82
- Max
- 1.42
- GMAB
- 0.82
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.04
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- SMMT
- 0.04
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | GMAB | SMMT |
|---|---|---|
| Current Ratio (MRQ) | 2.45 | 5.99 |
| Debt / Equity (MRQ) | 0.82 | 0.04 |
| Net Debt / EBITDA | 2.45 | -- |
Dividends
Dividend Yield (TTM)
Neither Genmab (GMAB) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- GMAB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- SMMT
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Genmab (GMAB) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- GMAB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- SMMT
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | GMAB | SMMT |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Genmab (GMAB) trades at 45.84 times trailing earnings, ranked against its peers, while Summit Therapeutics (SMMT) has no P/E ratio this period.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
45.84
- Max
- 85.34
- GMAB
- 45.84
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- SMMT
- --
P/S Ratio (TTM)
A sales-based read is only available for Genmab (GMAB), whose P/S ratio of 7.68 ranks against industry peers; Summit Therapeutics (SMMT) reports no figure this period.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.68
- Max
- 58.18
- Q3
- 25.77
- GMAB
- 7.68
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
- SMMT
- --
P/B Ratio (MRQ)
Genmab (GMAB) at 5.36 sits near its industry’s typical P/B ratio, while Summit Therapeutics (SMMT) at 23.13 prices above its benchmark range — SMMT looks rich relative to book.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.36
- Max
- 13.53
- Q3
- 6.54
- GMAB
- 5.36
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.13
- SMMT
- 23.13
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | GMAB | SMMT |
|---|---|---|
| P/E Ratio (TTM) | 45.84 | -- |
| P/S Ratio (TTM) | 7.68 | -- |
| P/B Ratio (MRQ) | 5.36 | 23.13 |
| Free Cash Flow Yield (TTM) | 2.59% | -1.64% |